Vimarsana
Biggest News Aggregation in the World

Page 19 - Double Blind News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Double Blind. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Double Blind Today - Breaking & Trending Today

Lawmakers Propose to Legalize Magic Mushrooms in New York State - Vimarsana News

Lawmakers Propose to Legalize Magic Mushrooms in New York State

Three lawmakers are looking to pass the bill in the state this year.

Source: wrrv.com
ACTRIMS 2023: GA Depot reduces MS relapses in Phase 3 trial | Long-acting glatiramer acetate also helps ease patients' disability - Vimarsana News

ACTRIMS 2023: GA Depot reduces MS relapses in Phase 3 trial | Long-acting glatiramer acetate also helps ease patients' disability

The long-acting glatiramer acetate therapy GA Depot was found to ease disability in patients with relapsing forms of MS in a Phase 3 trial.

In the Tropical Gothclub with Dean Fertita - Vimarsana News

In the Tropical Gothclub with Dean Fertita

While balancing multiple high-profile gigs, the multi-instrumentalist and A-list sideman Dean Fertita has taken a step forward in his solo career with his first solo outing in over a decade. The anticipated Tropical Gothclub, released in late 2022, is his first record since 2009’s Hello=Fire, and features a mixture of harmonized leads, propulsive energy, and more trippy, dreamy moments.

Ground-breaking results in Phase 2 scleroderma study by Certa Therapeutics demonstrates improvement in more than 60% of patients - Vimarsana News

Ground-breaking results in Phase 2 scleroderma study by Certa Therapeutics demonstrates improvement in more than 60% of patients

Data from Certa Therapeutics' Phase 2 clinical trial with development candidate FT011 demonstrates clinically meaningful improvements for more than 60 percent of patients with scleroderma after 12 weeks of treatment; Clinically meaningful improvements were reported in CRISS (the key composite endpoint for systemic sclerosis) lung function, SHAQ-DI and Physician Global Assessment; The trial results also showed FT011 to be safe and well tolerated in this patient population; FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs; Certa's nov...

Nektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting - Vimarsana News

Nektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced two presentations of NKTR-255 at the 64th American Society of Hematology (ASH) Annual...